The nasal spray vaccine has been off the USA market for two years because it barely worked against one common strain of flu in kids.
It's been off the market for two years because of its poor performance compared to the flu shot.
This flu season has been one of the deadliest in recent memory.
The advisory committee voted 12-2 Wednesday to approve and recommend the nasal spray for the next flu season.
AstraZeneca presented positive results from a U.S. study in children between 2 and 4 years old that evaluated their responses to the H1N1 strain in the quadrivalent formula of the spray which protects against four different influenza viruses.
AstraZeneca says it will supply FluMist to the US market next season.
FluMist is a live attenuated influenza vaccine.
Dr. Len Horovitz, a pulmonary specialist from Lenox Hill Hospital in New York City, concurred.
But Grohskopf pointed out that no one can know that until there's a flu season in which H1N1 is the dominant strain.
"This is not an easy decision", said Dr. Nancy Bennett, chair of the Advisory Committee on Immunization Practices (ACIP), whose decision guide which vaccines are available on the US market.
All eyes are now on the reformulated FluMist's effectiveness, as experts have anxious that poor effectiveness will turn people off flu vaccines.
This year's 2017-18 seasonal flu shot has been just 36% effective against both A and B virus strains, the CDC estimated in a midseason report. So far in the 2017-2018 season, six children have died from the flu.
But the new, small study seems to show FluMist's effectiveness has improved.
"In all, we want to give parents and children the broadest choice possible for influenza prevention", said Neuzil, a professor of medicine and pediatrics and director of the Center for Vaccine Development at the University of Maryland School of Medicine. After a second dose, those results increased to 45 percent, the company said.